jamaicanholiday's Comments jamaicanholiday's Comments RSS Syndication from SeekingAlpha.com http://seekingalpha.com/user/611917/comments Will Influenza A H7N9 Generate Opportunities For Pharma? http://seekingalpha.com/article/1449531/comments?source=feed#comment-19079591 19079591 NVAX) in this area. They use VLP technology (vs egg based) and claim they can turnaround vaccines much more quickly with this technology. If true, they could be a strong candidate for any pandemic responses.]]> Tue, 21 May 2013 13:45:52 -0400 NVAX) in this area. They use VLP technology (vs egg based) and claim they can turnaround vaccines much more quickly with this technology. If true, they could be a strong candidate for any pandemic responses.]]> Jamba Squeezing Up A Turnaround http://seekingalpha.com/article/1391381/comments?source=feed#comment-18334591 18334591 Wed, 01 May 2013 17:58:34 -0400 Shares of Jamba (JMBA) fall 16.2% premarket in thin trading. Last week's Q4 report from the company was a mixed bag with gains at franchises offsetting a sales slip at company-owned stores. http://seekingalpha.com/currents/post/879401?source=feed#comment-16123841 16123841 Mon, 11 Mar 2013 09:10:20 -0400 Novavax (NVAX): Q4 EPS of -$0.06 misses by $0.01. Revenue of $4.56M misses by $2.48M. (PR) http://seekingalpha.com/currents/post/861801?source=feed#comment-15679441 15679441 Fri, 01 Mar 2013 08:37:27 -0500 Jamba (JMBA) outlined its strategic priorities for 2013 at the ICR XChange Conference, saying it will put a new business model in place to ramp up the manufacturing and distribution of its branded products globally. With the new drivers in place, the company expects to see comparable store sales rise 4% to 6% in FY13 and store-level margin to reach 20%. (webcast) http://seekingalpha.com/currents/post/765261?source=feed#comment-13785911 13785911 Wed, 16 Jan 2013 13:19:58 -0500 Krispy Kreme (KKD) and Jamba (JMBA) look like tasty takeover candidates with sales in coffee and beverage chains outpacing other restaurant sectors, according to a Bloomberg piece. Analysts think the well-known brands could fetch a cozy premium. JMBA +4.9% premarket off the M&A chatter. http://seekingalpha.com/currents/post/747831?source=feed#comment-13388251 13388251 Mon, 07 Jan 2013 08:37:08 -0500 The Worst-Run Company List Of 2012 http://seekingalpha.com/article/1049401/comments?source=feed#comment-12458311 12458311 Mon, 10 Dec 2012 17:27:53 -0500 'Super' Novavax: Company Outshines Stars Of Pandemic Influenza Vaccine Production http://seekingalpha.com/article/1006621/comments?source=feed#comment-11843061 11843061 Wed, 21 Nov 2012 08:59:58 -0500 'Super' Novavax: Company Outshines Stars Of Pandemic Influenza Vaccine Production http://seekingalpha.com/article/1006621/comments?source=feed#comment-11828051 11828051
The vaccine, produced by Novartis AG, (NVS, NOVN.VX), was made using cultured animal cells, which is a technology that has been used for other types of vaccines for several decades. The FDA said an advantage of this technology is the potential for the vaccine manufacturing process to begin faster in the event of a flu pandemic.

The vaccine will be sold with the brand name Flucelvax and is approved for use in adults ages 18 and older.

Seasonal influenza vaccines are typically designed to protect against three or four viruses that can cause the illness. Traditionally, the virus strains included in each year's vaccine are grown in chicken eggs, which are injected with influenza viruses and incubated for 11 days in order to produce the active ingredient in the vaccines. It takes about six to nine months for vaccine to be made and tested.

Flucelvax will eventually be made at a new Novartis vaccine plant in Holly Springs N.C., which received almost $500 million from the U.S. government in 2006 as part of a project to improve vaccine production and prepare for a pandemic. Other companies also received funding.

The Holly Spring plant will use a cell-culture system derived from a dog kidney that can be continually grown in a laboratory, which cuts as much as a month off the start of the egg-based process. Novartis has a plant in Germany that also uses the same cell-based technology.

The cells are infected with influenza viruses, which grow in 1,250-gallon steel tanks for three days before being extracted and purified and later placed inside a shot. Cell cultures also eliminate the need for a continual supply of chicken eggs.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjo...]]> Tue, 20 Nov 2012 18:27:29 -0500
The vaccine, produced by Novartis AG, (NVS, NOVN.VX), was made using cultured animal cells, which is a technology that has been used for other types of vaccines for several decades. The FDA said an advantage of this technology is the potential for the vaccine manufacturing process to begin faster in the event of a flu pandemic.

The vaccine will be sold with the brand name Flucelvax and is approved for use in adults ages 18 and older.

Seasonal influenza vaccines are typically designed to protect against three or four viruses that can cause the illness. Traditionally, the virus strains included in each year's vaccine are grown in chicken eggs, which are injected with influenza viruses and incubated for 11 days in order to produce the active ingredient in the vaccines. It takes about six to nine months for vaccine to be made and tested.

Flucelvax will eventually be made at a new Novartis vaccine plant in Holly Springs N.C., which received almost $500 million from the U.S. government in 2006 as part of a project to improve vaccine production and prepare for a pandemic. Other companies also received funding.

The Holly Spring plant will use a cell-culture system derived from a dog kidney that can be continually grown in a laboratory, which cuts as much as a month off the start of the egg-based process. Novartis has a plant in Germany that also uses the same cell-based technology.

The cells are infected with influenza viruses, which grow in 1,250-gallon steel tanks for three days before being extracted and purified and later placed inside a shot. Cell cultures also eliminate the need for a continual supply of chicken eggs.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjo...]]> 'Super' Novavax: Company Outshines Stars Of Pandemic Influenza Vaccine Production http://seekingalpha.com/article/1006621/comments?source=feed#comment-11723591 11723591 Sat, 17 Nov 2012 12:57:28 -0500 'Super' Novavax: Company Outshines Stars Of Pandemic Influenza Vaccine Production http://seekingalpha.com/article/1006621/comments?source=feed#comment-11723521 11723521 Sat, 17 Nov 2012 12:55:03 -0500 'Super' Novavax: Company Outshines Stars Of Pandemic Influenza Vaccine Production http://seekingalpha.com/article/1006621/comments?source=feed#comment-11649431 11649431 Thu, 15 Nov 2012 13:38:56 -0500 'Super' Novavax: Company Outshines Stars Of Pandemic Influenza Vaccine Production http://seekingalpha.com/article/1006621/comments?source=feed#comment-11646551 11646551 Thu, 15 Nov 2012 12:40:00 -0500 'Super' Novavax: Company Outshines Stars Of Pandemic Influenza Vaccine Production http://seekingalpha.com/article/1006621/comments?source=feed#comment-11645241 11645241 Thu, 15 Nov 2012 12:16:49 -0500 Jamba Juice (JMBA +0.5%) plans to follow up on its first year of profitability as a public company with a sweeping plan to grow sales and traffic. For the full-year, the company sees opening 40-50 Jamba Juice system stores, up to 15 international stores, 400-500 JambaGO automated outlets, as well as three spanking-new concept stores. In terms of numbers, the company has a leg up on Starbucks' Evolution Fresh juice business, but the juice market looks to be heating up with more competition. http://seekingalpha.com/currents/post/644231?source=feed#comment-11304461 11304461 Tue, 06 Nov 2012 19:05:36 -0500 Jamba (JMBA): Q3 EPS of $0.04 misses by $0.03. Revenue of $65.5M (+14.7% Y/Y) in-line. (PR) http://seekingalpha.com/currents/post/632871?source=feed#comment-11145121 11145121 Thu, 01 Nov 2012 20:05:04 -0400 With Turnaround Complete Jamba Juice Shares Have Multi-Bagger Potential http://seekingalpha.com/article/875701/comments?source=feed#comment-9645311 9645311 Wed, 19 Sep 2012 21:19:22 -0400 Jamba: Earnings, A Disappointment http://seekingalpha.com/article/772661/comments?source=feed#comment-8014801 8014801
considering the author is disclosed as short, smart investors will question his thesis.]]> Thu, 02 Aug 2012 07:21:44 -0400
considering the author is disclosed as short, smart investors will question his thesis.]]> Jamba (JMBA): Q2 EPS of $0.05 misses by $0.02. Revenue of $66M (+12.1% Y/Y) misses by $1.3M. (PR) http://seekingalpha.com/currents/post/457151?source=feed#comment-8009471 8009471 Wed, 01 Aug 2012 22:53:48 -0400 Jamba (JMBA): Q2 EPS of $0.05 misses by $0.02. Revenue of $66M (+12.1% Y/Y) misses by $1.3M. (PR) http://seekingalpha.com/currents/post/457151?source=feed#comment-8009441 8009441 Wed, 01 Aug 2012 22:52:45 -0400 3 Reasons To Buy Novavax http://seekingalpha.com/article/680981/comments?source=feed#comment-6759701 6759701 Mon, 25 Jun 2012 08:19:33 -0400 Jamba (JMBA -2.9%) keeps pushing forward despite what was considered an ominous entry into the Smoothie market by Starbucks and McDonald's. A Q1 same-store sales increase of 12.7% was boosted by higher traffic and an increase in the average check, while the firm has kept firmly in place an aggressive plan to double global stores this year. JMBA +49.4% YTD. http://seekingalpha.com/currents/post/315641?source=feed#comment-5430561 5430561 Mon, 14 May 2012 17:19:35 -0400 Is The Novavax 'New Paradigm' Worth A Second Look? http://seekingalpha.com/article/559601/comments?source=feed#comment-5097441 5097441
looking for big news on Partnership or other relationship with major Pharma before the end of Q2 this year.]]> Fri, 04 May 2012 10:47:45 -0400
looking for big news on Partnership or other relationship with major Pharma before the end of Q2 this year.]]> Novavax (NVAX): Q1 EPS of -$0.06 misses by $0.02. Revenue of $4.64M (+475% Y/Y) beats by $0.2M. Shares +6.7% premarket. (PR) http://seekingalpha.com/currents/post/297261?source=feed#comment-5093131 5093131 Fri, 04 May 2012 09:15:52 -0400 8 Reasons To Buy This $1.30 Lottery Ticket http://seekingalpha.com/article/425291/comments?source=feed#comment-3378091 3378091 Sun, 11 Mar 2012 13:01:28 -0400 Jamba: Stick To The Smoothies, Skip The Stock http://seekingalpha.com/article/318739/comments?source=feed#comment-2163701 2163701
need to make a few more changes and such, but the brand is solid and has value. a nice, low-risk bolt on to any larger company looking to expand, get into healthy lifestyles restaurant alternative.

also your view is contrary to other Seeking Alpha authors who see JMBA as greatly undervalued.

$4.00 by end 2012.]]> Tue, 10 Jan 2012 21:07:32 -0500
need to make a few more changes and such, but the brand is solid and has value. a nice, low-risk bolt on to any larger company looking to expand, get into healthy lifestyles restaurant alternative.

also your view is contrary to other Seeking Alpha authors who see JMBA as greatly undervalued.

$4.00 by end 2012.]]> Computer Sciences Corp: Upward Trajectory Will Continue http://seekingalpha.com/article/247510/comments?source=feed#comment-1422854 1422854 Sun, 23 Jan 2011 13:19:11 -0500